全文获取类型
收费全文 | 2009篇 |
免费 | 189篇 |
国内免费 | 12篇 |
专业分类
耳鼻咽喉 | 15篇 |
儿科学 | 95篇 |
妇产科学 | 53篇 |
基础医学 | 130篇 |
口腔科学 | 43篇 |
临床医学 | 220篇 |
内科学 | 551篇 |
皮肤病学 | 11篇 |
神经病学 | 57篇 |
特种医学 | 209篇 |
外科学 | 292篇 |
综合类 | 36篇 |
预防医学 | 47篇 |
眼科学 | 17篇 |
药学 | 43篇 |
中国医学 | 5篇 |
肿瘤学 | 386篇 |
出版年
2023年 | 7篇 |
2022年 | 15篇 |
2021年 | 44篇 |
2020年 | 18篇 |
2019年 | 25篇 |
2018年 | 53篇 |
2017年 | 69篇 |
2016年 | 53篇 |
2015年 | 62篇 |
2014年 | 72篇 |
2013年 | 99篇 |
2012年 | 100篇 |
2011年 | 93篇 |
2010年 | 90篇 |
2009年 | 123篇 |
2008年 | 103篇 |
2007年 | 94篇 |
2006年 | 85篇 |
2005年 | 73篇 |
2004年 | 62篇 |
2003年 | 50篇 |
2002年 | 34篇 |
2001年 | 51篇 |
2000年 | 31篇 |
1999年 | 24篇 |
1998年 | 66篇 |
1997年 | 63篇 |
1996年 | 64篇 |
1995年 | 58篇 |
1994年 | 39篇 |
1993年 | 45篇 |
1992年 | 31篇 |
1991年 | 28篇 |
1990年 | 29篇 |
1989年 | 25篇 |
1988年 | 32篇 |
1987年 | 26篇 |
1986年 | 19篇 |
1985年 | 12篇 |
1984年 | 18篇 |
1983年 | 19篇 |
1981年 | 16篇 |
1980年 | 10篇 |
1979年 | 10篇 |
1978年 | 10篇 |
1977年 | 12篇 |
1976年 | 10篇 |
1975年 | 7篇 |
1974年 | 8篇 |
1970年 | 5篇 |
排序方式: 共有2210条查询结果,搜索用时 46 毫秒
1.
Benign intracranial hypertension and recombinant growth hormone therapy in Australia and New Zealand
PA Crock JD McKenzie AM Nicoll NJ Howard W Cutfield LK Shield G Byrne 《Acta paediatrica (Oslo, Norway : 1992)》1998,87(4):381-386
Benign intracranial hypertension (BIH) is reported in three children from Australia and one from New Zealand, who were being treated with recombinant human growth hormone (rhGH). Three males and one female, aged between 10.5 and 14.2 y, developed intracranial hypertension within 2 weeks to 3 months of starting treatment. A national database, OZGROW, has been prospectively collecting data on all 3332 children treated with rhGH in Australia and New Zealand from January 1986 to 1996. The incidence of BIH in children treated with growth hormone (GH) is small, 1.2 per 1000 cases overall, but appears to be greater with biochemical GHD (<10IUml -1 ), i.e. 6.5/1000 (3 in 465 cases), relative risk 18.4, 95% confidence interval 1.9-176.1, than in all other children on the database. The incidence in patients with Turner's syndrome was 2.3/1000 (1 in 428 cases). No cases in patients with partial GHD (10–20 IUml -1 ) or chronic renal failure were identified. Possible causative mechanisms are discussed. The authors'practice is now to start GH replacement at less than the usual recommended dose of 14IUm-2 week-1 in those children considered to be at high risk of developing BIH. Ophthalmological evaluation is recommended for children before and during the first few months following commencement of rhGH therapy and is mandatory in the event of peripheral or facial oedema, persistent headaches, vomiting or visual symptoms. The absence of papilledema does not exclude the diagnosis. 相似文献
2.
Complete testicular feminisation syndrome in three sisters 总被引:1,自引:0,他引:1
3.
D Pantazopoulos P Karagiannakos F Sofras A Kostakopoulos C Deliveliotis C Dimopoulos 《Urology》1990,36(3):255-259
The normal urothelium is covered by a glycosaminoglycan (GAG) layer which acts as a barrier to the adhesion of crystals. Destruction of the GAG layer increases the number of adhered crystals, and it is therefore assumed that it promotes crystal growth and stone formation. Intravesical instillation of pentosanpolysulfate, an exogenous glycosaminoglycan, after destruction of this layer reduces the adhesion of crystals to the urothelium. Intramuscular administration of carbenoxolone sodium following the experimental destruction of the GAG layer increases the rate of healing of the layer and reduces the number of adhered crystals. 相似文献
4.
Cyclophosphamide and etoposide therapy with GM-CSF for VAD-resistant multiple myeloma 总被引:1,自引:0,他引:1
Meletios A. Dimopoulos Kay B. Delasalle Richard Champlin Raymond Alexanian 《British journal of haematology》1993,83(2):240-244
Few effective regimens are available for patients with advanced multiple myeloma resistant to or relapsing after both alkylating agents and VAD. We treated 52 patients with advanced and refractory multiple myeloma with the combination of cyclophosphamide (3.0 g/m2 ) and etoposide (900 mg/m2 ) followed by GM-CSF at a daily dose of 0.125 mg/m2 until recovery of granulocytes. 42% of patients responded with a median time of 19 d for recovery of granulocytes to 0.5 x 109 /1 and a 4% mortality rate. Eight responding patients received a second myeloablative treatment supported by either autologous bone marrow (six patients) or blood stem cells (two patients). The median survival time for all patients was 11 months and the median remission time for responding patients was 8 months. The combination of cyclophosphamide and etoposide provided an effective rescue treatment for many patients with advanced multiple myeloma resistant to conventional therapies. This programme also allowed early marrow or blood stem cell collection in support of subsequent myeloablative therapy for selected patients. 相似文献
5.
In a prospective, randomized, double-blind study, 49 patients underwent lumbar myelography using iotrol (24 patients) or metrizamide (25 patients). The diagnostic imaging adequacy of iotrol was comparable with that of metrizamide. After iotrol myelography, adverse reactions were fewer, less severe, and of shorter duration than were those following metrizamide myelography. Thirteen of 24 patients (54%) receiving iotrol reported some adverse reactions compared with 24 of 25 patients (96%) receiving metrizamide. Five moderate and one severe adverse reaction occurred in the group receiving iotrol. Fourteen moderate and eight severe adverse reactions occurred in the group receiving metrizamide. Thirty-eight patients underwent electroencephalography both before and after myelography (19 iotrol and 19 metrizamide). None of the EEGs obtained after iotrol myelography changed from baseline, while seven of the EEGs obtained after metrizamide myelography showed changes from baseline. Iotrol was judged superior to metrizamide as a contrast medium in this patient population. 相似文献
6.
7.
8.
D. Peres-Bota H. Rodriguez-Villalobos G. Dimopoulos C. Melot J.-L. Vincent 《Clinical microbiology and infection》2004,10(6):550-555
The incidence, risk factors and prognostic factors for candidal infection were determined in a prospective study of 280 infected patients. Thirty-one (11%) patients were infected with Candida spp., sub-divided into 18 (58%) with C. albicans, and 13 (42%) with non-albicans spp. (six C. glabrata, three C. parapsilosis, and one each of C. krusei, C. tropicalis, C. guilliermondii and C. lusitaniae). Infection with Candida spp. was always associated with concurrent bacterial infection. By univariate logistic regression analysis, the degree of morbidity and the duration of mechanical ventilation were independent predictive factors for death, but infection with Candida spp., was not. Factors associated with Candida spp. infection were the degree of morbidity, intensive care unit length of stay, alterations of immune response, and the number of medical devices involved. By multivariate logistic regression analysis, the only independent risk factor for candidal infection was intensive care unit length of stay. 相似文献
9.
臂丛神经根性损伤膈神经移位术对青壮年患者早期呼吸功能的影响 总被引:1,自引:1,他引:0
目的研究臂丛神经损伤膈神经移位术对青壮年患者早期呼吸功能的影响.方法对16例接受膈神经移位治疗的患者,在术前、术后(10 d)进行肺功能指标的比较,同时定期进行门诊随访,观察呼吸系统自觉症状程度.结果13例术后出现了不同程度的供氧不足症状,16例全部出现一侧膈肌抬高,术后第10天肺活量(VC)、肺活量预计值百分数(VC%)分别比术前减少37.98%和26.88%,两者差异有统计学意义(tvc=11.532、tvc%=0,P<0.01).其它项目如残气量(RV)较术前轻度下降,肺总量(TLC)下降值达到术前肺总量的36.49%,残气量/肺总量比值(RV/TLC%)较术前上升了4.75%,上述各指标的差值均有统计学意义.1 s用力呼气量/用力肺活量比值(FEV1/FVC)和术前比基本无改变,但其差值有统计学意义.膈神经移位右侧(10例)与左侧(6例)术前、术后肺活量比较差异有统计学意义.术后随访8个月~2年,所有患者均无明显呼吸困难和胸闷等症状.结论膈神经移位术后对青壮年患者肺容量有较大的丧失,肺通气功能减弱和小气道阻力增加,但其丧失程度在机体自身代偿耐受范围内,不会导致急剧发生的严重呼吸功能障碍.建议对右侧臂丛神经根性损伤的患者,术前进行严格的肺、心功能检查,避免发生较为严重的并发症. 相似文献
10.